Endpoint

Population

Vaccine Efficacy
(95% CI)

Average time of follow up

Reference

Persistent infection caused by HPV 6/11/16/18

PPii

96% (83, 100)

5 yr

76

CIN 1+ caused by HPV 6/11/16/18¶

PE

100% (13, 100)

40 mo

28

CIN 2+ caused by HPV 16/18

PPSP

98% (94, 100)

3.5 yrs

33

CIN 2+ caused by HPV 16/18

USP

95% (85, 99)

3.5 yrs

33

CIN 2+ caused by HPV 16/18

ITT

44% (26-58)

3.5 yrs

33

CIN 2+ caused by any HPV type

ITT

18% (7, 28)

3.5 yrs

33

CIN 2+ caused by any HPV type

NPS

43% (24, 57)

3.6 yrs

21

VIN 2/3 caused by HPV 16/18

PP

100% (56, 100)

44 mo

33

VaIN 2/3 caused by HPV 16/18

PP

100% (50, 100)

44 mo

33

VIN 2/3 caused by any HPV type§

ITT

50% (9, 73)

44 mo

33

VaIN 1 caused by HPV 6/11/16/18†

PP

100% (31, 100)

36 mo

77

VIN 1, VaIN 1 or condyloma caused by any HPV

ITT

41% (28, 51)

36 mo

77

Condyloma caused by HPV 6/11/16/18

PP

99% (96, 100)

44 mo

33

Condyloma caused by any HPV type

PP

83% (74, 89)

44 mo

33

Condyloma caused by HPV 6/11/16/18

PE

100% (28, 100)

40 mo

28

Male condyloma caused by HPV 6/11/16/18

PPE

89% (66-98)

29 mo

34

Male condyloma caused by HPV 6*

PPE

84% (47, 97)

29 mo

34

Male condyloma caused by HPV 11*

PPE

91% (38, 100)

29 mo

34

PPii means per-protocol: seronegative and PCR negative to HPV 6, 11, 16, 18 at baseline, remained PCR negative for vaccine relevant type through one month post dose
3 and received three doses within one year; cases were counted starting one month after three doses given.
PPSP means per protocol susceptible population: for those women who were seronegative and PCR negative for the vaccine related HPV types at study entry regardless
of entry cytology results, remained PCR negative for the vaccine relevant HPV types through one month after receipt of the third injection; cases counted one month after
three doses given.
USP means unrestricted susceptible population: for those women who were seronegative and PCR negative for the vaccine related HPV types at study entry regardless of
entry cytology results, received one or more injections, cases counted from the first day after the first injection.
ITT means intention to treat population: regardless of serostatus or HPV DNA PCR status to vaccine relevant HPV types at study entry, regardless of entry cytology,
regardless of timing and number of injections received, cases were counted from day 1 after the first injection.
NPS means naive population simulation: women were seronegative to HPV 6/11/16/18 and PCR negative to HPV 6/11/16/18/31/33/35/39/45/51/52/56/58/59 at baseline,
had a normal Pap at baseline, received at least one injection, had at least one follow up visit; cases counted after day 1.
PP means Per Protocol: women were seronegative at baseline and PCR negative for each type Day 1 through Month 7, regardless of entry cytology; cases were counted
from the first day after 30 days after the third injection.
PPE means per protocol for efficacy in male trials: seronegative and PCR negative to the relevant HPV type at Day 1, Free of infection with the relevant HPV type through
Month 7, Received all 3 doses; cases were counted from the first day after 30 days after the third injection.
PE means previously exposed population: women who were seropositive for HPV 6/11/16/18 and were PCR negative for HPV 6/11/16/18 at baseline.
*Male condyloma caused by HPV 16 or 18 were not statistically significant
†VIN 1 caused by HPV 6/11/16/18 was not statistically significant
§Vain 2/3 caused by any HPV type was not statistically significant
¶CIN 2+, CIN 3+, AIS. VIN 1, VIN 2+, VaIN 1, VaIN 2+ caused by HPV 6/11/16/18 were not statistically significant
Table 3: Significant Efficacies for Gardasil by Endpoint, Population and Time of Follow Up.